Taiko Pharmaceutical Co.,Ltd. (4574.T)
JPY 276.0
(1.1%)
JPY 276.0
(1.1%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2022 | -4.89 Billion JPY | 48.98% |
| 2021 | -9.59 Billion JPY | -349.07% |
| 2020 | 3.85 Billion JPY | 56.98% |
| 2019 | 2.45 Billion JPY | 73.33% |
| 2018 | 1.41 Billion JPY | 29.27% |
| 2017 | 1.09 Billion JPY | 4.34% |
| 2016 | 1.04 Billion JPY | 24.91% |
| 2015 | 840.11 Million JPY | -52.55% |
| 2014 | 1.77 Billion JPY | 1.33% |
| 2013 | 1.74 Billion JPY | 68.4% |
| 2012 | 1.03 Billion JPY | 115.16% |
| 2011 | 482.2 Million JPY | 121.64% |
| 2010 | -2.22 Billion JPY | -235.44% |
| 2009 | 1.64 Billion JPY | 249.45% |
| 2008 | 470.77 Million JPY | 30.61% |
| 2007 | 360.43 Million JPY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 Q3 | -48 Million JPY | 82.29% |
| 2023 Q2 | -271 Million JPY | -11.52% |
| 2023 Q1 | -243 Million JPY | 85.81% |
| 2022 Q3 | -384 Million JPY | 63.39% |
| 2022 FY | -4.89 Billion JPY | 48.98% |
| 2022 Q4 | -1.71 Billion JPY | -346.09% |
| 2022 Q1 | -1.74 Billion JPY | 77.14% |
| 2022 Q2 | -1.04 Billion JPY | 39.99% |
| 2021 Q1 | -147 Million JPY | 0.0% |
| 2021 Q2 | -2.22 Billion JPY | -1413.61% |
| 2021 FY | -9.59 Billion JPY | -349.07% |
| 2021 Q4 | -7.64 Billion JPY | -1899.29% |
| 2021 Q3 | 425 Million JPY | 119.1% |
| 2020 FY | 3.85 Billion JPY | 56.98% |
| 2020 Q1 | 326.57 Million JPY | -78.01% |
| 2020 Q3 | 988.38 Million JPY | -47.16% |
| 2020 Q2 | 1.87 Billion JPY | 472.72% |
| 2019 Q2 | 103.08 Million JPY | -20.06% |
| 2019 FY | 2.45 Billion JPY | 73.33% |
| 2019 Q1 | 128.95 Million JPY | -84.62% |
| 2019 Q3 | 538.61 Million JPY | 422.5% |
| 2019 Q4 | 1.48 Billion JPY | 175.74% |
| 2018 Q4 | 838.52 Million JPY | 104.91% |
| 2018 Q3 | 409.22 Million JPY | 955.05% |
| 2018 Q1 | -58.62 Million JPY | -106.68% |
| 2018 Q2 | 38.78 Million JPY | 166.16% |
| 2018 FY | 1.41 Billion JPY | 29.27% |
| 2017 Q3 | 176.31 Million JPY | 76.67% |
| 2017 Q2 | 99.79 Million JPY | 149.3% |
| 2017 Q1 | -202.43 Million JPY | -120.3% |
| 2017 FY | 1.09 Billion JPY | 4.34% |
| 2017 Q4 | 877.47 Million JPY | 397.69% |
| 2016 Q4 | 997.45 Million JPY | 244.28% |
| 2016 FY | 1.04 Billion JPY | 24.91% |
| 2016 Q3 | 289.72 Million JPY | 920.18% |
| 2016 Q2 | -35.32 Million JPY | -153.9% |
| 2016 Q1 | 65.54 Million JPY | -89.93% |
| 2015 Q2 | 50.67 Million JPY | 248.42% |
| 2015 Q1 | -34.14 Million JPY | -103.1% |
| 2015 Q4 | 651.17 Million JPY | 795.48% |
| 2015 FY | 840.11 Million JPY | -52.55% |
| 2015 Q3 | 72.71 Million JPY | 43.5% |
| 2014 Q4 | 1.1 Billion JPY | 156.13% |
| 2014 Q3 | 430.4 Million JPY | 58.3% |
| 2014 Q1 | -171.14 Million JPY | -121.35% |
| 2014 Q2 | 271.89 Million JPY | 258.87% |
| 2014 FY | 1.77 Billion JPY | 1.33% |
| 2013 Q1 | -210.01 Million JPY | -126.64% |
| 2013 FY | 1.74 Billion JPY | 68.4% |
| 2013 Q2 | 529.11 Million JPY | 351.94% |
| 2013 Q4 | 801.72 Million JPY | 36.46% |
| 2013 Q3 | 587.53 Million JPY | 11.04% |
| 2012 Q4 | 788.37 Million JPY | 168.81% |
| 2012 Q2 | 165.88 Million JPY | 175.14% |
| 2012 FY | 1.03 Billion JPY | 115.16% |
| 2012 Q1 | -220.76 Million JPY | -174.12% |
| 2012 Q3 | 293.27 Million JPY | 76.79% |
| 2011 Q3 | 202.06 Million JPY | -0.49% |
| 2011 Q2 | 203.05 Million JPY | 115.56% |
| 2011 FY | 482.2 Million JPY | 121.64% |
| 2011 Q1 | -1.3 Billion JPY | -509.84% |
| 2011 Q4 | 297.85 Million JPY | 47.41% |
| 2010 Q3 | -586.35 Million JPY | -375.88% |
| 2010 Q1 | -283.06 Million JPY | -137.97% |
| 2010 Q4 | -213.94 Million JPY | 63.51% |
| 2010 FY | -2.22 Billion JPY | -235.44% |
| 2010 Q2 | -123.21 Million JPY | 56.47% |
| 2009 Q4 | 745.46 Million JPY | 10.47% |
| 2009 Q3 | 674.82 Million JPY | 32.87% |
| 2009 Q2 | 507.88 Million JPY | 618.59% |
| 2009 Q1 | 70.67 Million JPY | -67.44% |
| 2009 FY | 1.64 Billion JPY | 249.45% |
| 2008 FY | 470.77 Million JPY | 30.61% |
| 2008 Q4 | 217.09 Million JPY | 0.0% |
| 2007 FY | 360.43 Million JPY | 0.0% |
| Name | Net Income | Net Income Difference |
|---|---|---|
| Pharma Foods International Co., Ltd. | 3.2 Billion JPY | 252.699% |
| Takeda Pharmaceutical Company Limited | 144.06 Billion JPY | 103.397% |
| Sumitomo Pharma Co., Ltd. | -314.96 Billion JPY | 98.446% |
| Shionogi & Co., Ltd. | 162.03 Billion JPY | 103.02% |
| Wakamoto Pharmaceutical Co.,Ltd. | 108.95 Million JPY | 4591.598% |
| Nippon Shinyaku Co., Ltd. | 25.85 Billion JPY | 118.932% |
| Kaken Pharmaceutical Co., Ltd. | 8.02 Billion JPY | 160.984% |
| Eisai Co., Ltd. | 42.4 Billion JPY | 111.541% |
| Morishita Jintan Co., Ltd. | 697 Million JPY | 802.152% |
| Hisamitsu Pharmaceutical Co., Inc. | 13.96 Billion JPY | 135.035% |
| Mochida Pharmaceutical Co., Ltd. | 4.54 Billion JPY | 207.631% |
| Fuso Pharmaceutical Industries,Ltd. | 1.37 Billion JPY | 455.41% |
| Nippon Chemiphar Co., Ltd. | -180 Million JPY | -2618.889% |
| Tsumura & Co. | 16.7 Billion JPY | 129.293% |
| Kissei Pharmaceutical Co., Ltd. | 11.16 Billion JPY | 143.853% |
| Torii Pharmaceutical Co., Ltd. | 4.11 Billion JPY | 218.815% |
| Towa Pharmaceutical Co., Ltd. | 16.17 Billion JPY | 130.26% |
| Fuji Pharma Co., Ltd. | 3.43 Billion JPY | 242.475% |
| Zeria Pharmaceutical Co., Ltd. | 7.73 Billion JPY | 163.301% |
| KYORIN Holdings, Inc. | 5.32 Billion JPY | 191.958% |
| Daito Pharmaceutical Co.,Ltd. | 3.29 Billion JPY | 248.528% |
| SymBio Pharmaceuticals Limited | -1.96 Billion JPY | -149.336% |
| MedRx Co., Ltd | -932 Million JPY | -425.107% |
| Mizuho Medy Co.,Ltd. | 3.77 Billion JPY | 229.669% |
| Solasia Pharma K.K. | -1.11 Billion JPY | -340.108% |
| Modalis Therapeutics Corporation | -2.39 Billion JPY | -104.614% |
| ASKA Pharmaceutical Holdings Co.,Ltd. | 7.54 Billion JPY | 164.864% |
| Sawai Group Holdings Co., Ltd. | 13.69 Billion JPY | 135.736% |
| Cyfuse Biomedical K.K. | -589.21 Million JPY | -730.602% |
| Toho Holdings Co., Ltd. | 20.65 Billion JPY | 123.692% |
| Koa Shoji Holdings Co.,Ltd. | 2.94 Billion JPY | 266.105% |